Your browser doesn't support javascript.
loading
A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer / 中华肿瘤杂志
Zhonghua zhong liu za zhi ; (12): 88-94, 2023.
Article in Zh | WPRIM | ID: wpr-969810
Responsible library: WPRO
ABSTRACT
Objective: To explore the application and efficacy of paclitaxel liposome in the treatment of advanced breast cancer among Chinese population in the real world. Methods: The clinical characteristics of patients with advanced breast cancer who received paclitaxel liposome as salvage treatment from January 1, 2016 to August 31, 2019 in 11 hospitals were collected and retrospectively analyzed. The primary outcome was progression free survival (PFS), and the secondary outcome included objective response rate (ORR) and safety. The survival curve was drawn by Kaplan-Meier analysis and the Cox regression model were used for the multivariate analysis. Results: Among 647 patients with advanced breast cancer who received paclitaxel liposome, the first-line treatment accounted for 43.3% (280/647), the second-line treatment accounted for 27.7% (179/647), and the third-line and above treatment accounted for 29.1% (188/647). The median dose of first-line and second-line treatment was 260 mg per cycle, and 240 mg in third line and above treatment. The median period of paclitaxel liposome alone and combined chemotherapy or targeted therapy is 4 cycles and 6 cycles, respectively. In the whole group, 167 patients (25.8%) were treated with paclitaxel liposome combined with capecitabine±trastuzumab (TX±H), 123 patients (19.0%) were treated with paclitaxel liposome alone (T), and 119 patients (18.4%) were treated with paclitaxel liposome combined with platinum ± trastuzumab (TP±H), 108 patients (16.7%) were treated with paclitaxel liposome combined with trastuzumab ± pertuzumab (TH±P). The median PFS of first-line and second-line patients (5.5 and 5.5 months, respectively) were longer than that of patients treated with third line and above (4.9 months, P<0.05); The ORR of the first line, second line, third line and above patients were 46.7%, 36.8% and 28.2%, respectively. Multivariate analysis showed that event-free survival (EFS) and the number of treatment lines were independent prognostic factors for PFS. The common adverse events were myelosuppression, gastrointestinal reactions, hand foot syndrome and abnormal liver function. Conclusion: Paclitaxel liposomes is widely used and has promising efficacy in multi-subtype advanced breast cancer.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Treatment Outcome / Paclitaxel / Capecitabine / Trastuzumab / Liposomes Limits: Female / Humans Language: Zh Journal: Zhonghua zhong liu za zhi Year: 2023 Type: Article
Full text: 1 Index: WPRIM Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Retrospective Studies / Treatment Outcome / Paclitaxel / Capecitabine / Trastuzumab / Liposomes Limits: Female / Humans Language: Zh Journal: Zhonghua zhong liu za zhi Year: 2023 Type: Article